Jerry Shapiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jerry Shapiro has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Kristen Lo Sicco
The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA
19 shared publications - Derek Maas
The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA
12 shared publications - Archie Spindler
The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA
11 shared publications Kristen Lo Sicco
The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York
11 shared publications- Isabella Zappi
The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA
10 shared publications - Carli Needle Lawrence
The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA
8 shared publications
Latest Publications
- Open Access
- 18 July 2026
- Published by S. Karger AG in Skin Appendage Disorders
- p. 1-5
Disconnect between Patient and Dermatologist Perceptions in Androgenetic Alopecia Therapy: Social Analysis across More than 100,000 Digital Conversations
Introduction: Individuals with alopecia encounter numerous treatment options and obtain guidance from both medical and nonmedical sources. Despite stronger clinical evidence for prescription therapies, many patients favor over-the-counter (OTC) products. We used large-scale social listening to characterize public sentiment toward androgenetic alopecia (AGA) treatments and compare perceptions of OTC and prescription modalities. Methods: Over 700,000 publicly available posts (March 2024–April 2025) from major online forums were captured using hair-loss-related keywords, filtered to approximately 143,000 human-authored conversations. These were analyzed for treatment associations, concerns, thematic content, and sentiment. OTC and prescription discussions were compared using chi-square testing (Bonferroni-corrected, two-sided α = 0.006). Results: Of included posts, 27,425 discussed prescription and 39,138 OTC therapies. Sentiment was dominated by frustration and anxiety, with low satisfaction. Prescription discussions more frequently referenced perceived lack of efficacy and side-effect concerns, whereas OTC discussions more often expressed positive themes, satisfaction, simplicity, and integration into personal routines. Prescription therapies were more commonly associated with skepticism, despair, and last-resort framing. Discussion: Public sentiment toward AGA treatments is largely negative and favors OTC therapies despite stronger evidence for prescription modalities. These perception gaps may contribute to delayed dermatologic care, underscoring the need for targeted education, expectation setting, and earlier engagement with evidence-based treatment.
- 18 July 2026
- Published by S. Karger AG in Skin Appendage Disorders
- p. 1-5
Open AccessDisconnect between Patient and Dermatologist Perceptions in Androgenetic Alopecia Therapy: Social Analysis across More than 100,000 Digital Conversations
Introduction: Individuals with alopecia encounter numerous treatment options and obtain guidance from both medical and nonmedical sources. Despite stronger clinical evidence for prescription therapies, many patients favor over-the-counter (OTC) products. We used large-scale social listening to characterize public sentiment toward androgenetic alopecia (AGA) treatments and compare perceptions of OTC and prescription modalities. Methods: Over 700,000 publicly available posts (March 2024–April 2025) from major online forums were captured using hair-loss-related keywords, filtered to approximately 143,000 human-authored conversations. These were analyzed for treatment associations, concerns, thematic content, and sentiment. OTC and prescription discussions were compared using chi-square testing (Bonferroni-corrected, two-sided α = 0.006). Results: Of included posts, 27,425 discussed prescription and 39,138 OTC therapies. Sentiment was dominated by frustration and anxiety, with low satisfaction. Prescription discussions more frequently referenced perceived lack of efficacy and side-effect concerns, whereas OTC discussions more often expressed positive themes, satisfaction, simplicity, and integration into personal routines. Prescription therapies were more commonly associated with skepticism, despair, and last-resort framing. Discussion: Public sentiment toward AGA treatments is largely negative and favors OTC therapies despite stronger evidence for prescription modalities. These perception gaps may contribute to delayed dermatologic care, underscoring the need for targeted education, expectation setting, and earlier engagement with evidence-based treatment.
- 8 July 2026
- Published by Springer Nature
- p. 169-180
Hair Disorders in Cancer Patients and Cancer Survivors
- 8 July 2026
- Published by Springer Nature
- p. 169-180
Hair Disorders in Cancer Patients and Cancer Survivors
- Open Access
- 27 June 2026
- Published by S. Karger AG in Skin Appendage Disorders
- p. 1-13
Revisiting Diffuse Unpatterned Alopecia: Reappraisal of a Controversial Diagnosis
Diffuse unpatterned alopecia (DUPA) is thought to represent an uncommon and incompletely characterized variant of androgenetic alopecia (AGA) marked by diffuse follicular miniaturization across the entire scalp, including the occipital region, which distinguishes it from classic patterned AGA and often precludes hair transplantation. In this review of the available literature on DUPA, we discuss its clinical presentation, diagnostic features, competing pathophysiologic hypotheses, and management considerations. Current evidence suggests DUPA typically presents with diffuse scalp thinning involving the frontal, vertex, temporal, parietal, and occipital regions, with trichoscopy demonstrating widespread follicular miniaturization without features of scarring alopecia. Diagnosis remains clinical because histopathologic criteria and standardized trichometric thresholds have not been established. Important mimickers include telogen effluvium and diffuse alopecia areata, making careful history, examination, trichoscopy, and occasional scalp biopsy essential. Management is primarily medical, emphasizing stabilization rather than regrowth, and includes topical or oral minoxidil with consideration of adjunctive therapies such as platelet-rich plasma, low-level light therapy, and possibly antiandrogen therapies in selected patients. Major knowledge gaps remain regarding epidemiology, pathology, diagnostic criteria, and treatment-specific outcomes. Further clinicopathologic, trichometric, and longitudinal studies are needed to clarify whether DUPA represents a distinct entity or a severe diffuse phenotype within the AGA spectrum.
- 27 June 2026
- Published by S. Karger AG in Skin Appendage Disorders
- p. 1-13
Open AccessRevisiting Diffuse Unpatterned Alopecia: Reappraisal of a Controversial Diagnosis
Diffuse unpatterned alopecia (DUPA) is thought to represent an uncommon and incompletely characterized variant of androgenetic alopecia (AGA) marked by diffuse follicular miniaturization across the entire scalp, including the occipital region, which distinguishes it from classic patterned AGA and often precludes hair transplantation. In this review of the available literature on DUPA, we discuss its clinical presentation, diagnostic features, competing pathophysiologic hypotheses, and management considerations. Current evidence suggests DUPA typically presents with diffuse scalp thinning involving the frontal, vertex, temporal, parietal, and occipital regions, with trichoscopy demonstrating widespread follicular miniaturization without features of scarring alopecia. Diagnosis remains clinical because histopathologic criteria and standardized trichometric thresholds have not been established. Important mimickers include telogen effluvium and diffuse alopecia areata, making careful history, examination, trichoscopy, and occasional scalp biopsy essential. Management is primarily medical, emphasizing stabilization rather than regrowth, and includes topical or oral minoxidil with consideration of adjunctive therapies such as platelet-rich plasma, low-level light therapy, and possibly antiandrogen therapies in selected patients. Major knowledge gaps remain regarding epidemiology, pathology, diagnostic criteria, and treatment-specific outcomes. Further clinicopathologic, trichometric, and longitudinal studies are needed to clarify whether DUPA represents a distinct entity or a severe diffuse phenotype within the AGA spectrum.
- Open Access
- 18 June 2026
- Published by S. Karger AG in Skin Appendage Disorders
- p. 1-19
Efficacy of Topical Tretinoin and Topical Minoxidil Cotherapy in Androgenetic Alopecia: A Review
Background: Androgenetic alopecia (AGA) frequently occurs in both men and women and is associated with a significant quality-of-life impairment. Topical minoxidil has been demonstrated to have a variable clinical response, and the proposed efficacy of using concomitant topical tretinoin largely stems from increased minoxidil penetration and activation by the follicular sulfotransferase enzyme. Summary: This review summarizes mechanisms, safety, outcomes, and social media perspectives on the subject. Pharmacokinetic evidence demonstrates a nearly threefold increase in systemic absorption when tretinoin cream is applied before minoxidil, with researchers hypothesizing increased permeability as the cause. However, clinical data regarding combination therapy is minimal. One randomized controlled trial reported similar outcomes between dual therapy and topical minoxidil monotherapy; results from smaller investigations, however, are consistent with the potential conversion of some minoxidil nonresponders to responders when tretinoin is used. A social media analysis of 71 online posts was notable for frequently positive claims regarding the interaction, but tolerability concerns were common. Key Messages: Though current evidence does not support the first-line use of dual therapy, topical tretinoin may be considered as an adjunct in AGA, especially in patients without response to topical minoxidil. Any potential benefit, however, should be weighed against the potential for increased irritation.
- 18 June 2026
- Published by S. Karger AG in Skin Appendage Disorders
- p. 1-19
Open AccessEfficacy of Topical Tretinoin and Topical Minoxidil Cotherapy in Androgenetic Alopecia: A Review
Background: Androgenetic alopecia (AGA) frequently occurs in both men and women and is associated with a significant quality-of-life impairment. Topical minoxidil has been demonstrated to have a variable clinical response, and the proposed efficacy of using concomitant topical tretinoin largely stems from increased minoxidil penetration and activation by the follicular sulfotransferase enzyme. Summary: This review summarizes mechanisms, safety, outcomes, and social media perspectives on the subject. Pharmacokinetic evidence demonstrates a nearly threefold increase in systemic absorption when tretinoin cream is applied before minoxidil, with researchers hypothesizing increased permeability as the cause. However, clinical data regarding combination therapy is minimal. One randomized controlled trial reported similar outcomes between dual therapy and topical minoxidil monotherapy; results from smaller investigations, however, are consistent with the potential conversion of some minoxidil nonresponders to responders when tretinoin is used. A social media analysis of 71 online posts was notable for frequently positive claims regarding the interaction, but tolerability concerns were common. Key Messages: Though current evidence does not support the first-line use of dual therapy, topical tretinoin may be considered as an adjunct in AGA, especially in patients without response to topical minoxidil. Any potential benefit, however, should be weighed against the potential for increased irritation.
- 26 May 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1)
Smoking, vaping, and perceived hair loss: a social media analysis with cessation counseling implications
- 26 May 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1)
Smoking, vaping, and perceived hair loss: a social media analysis with cessation counseling implications
- 13 May 2026
- Published by Taylor & Francis
- p. 32-35
Serums and Hair Styling Products
- 13 May 2026
- Published by Taylor & Francis
- p. 68-72
Permanent Hair Styles (“Perms”)